Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Higher versus standard adalimumab dosing in Crohn's disease with mucosal ulceration
NL-OMON47833Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in Crohn's disease (4 arms), sponsored by AbbVie Inc. Primary endpoints: Clinical remission at Week 4 and Endoscopic response at Week 12. Started Jan 2015; status: completed.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON47833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47833.